Pine Valley Investments Ltd Liability Co Purchases 128 Shares of Danaher Co. (NYSE:DHR)

Pine Valley Investments Ltd Liability Co grew its position in shares of Danaher Co. (NYSE:DHR) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,604 shares of the conglomerate’s stock after buying an additional 128 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in Danaher were worth $2,205,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DHR. FMR LLC increased its position in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Van ECK Associates Corp increased its position in shares of Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after purchasing an additional 916,513 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the period. Fisher Funds Management LTD bought a new position in shares of Danaher in the fourth quarter worth $120,718,000. Finally, Montrusco Bolton Investments Inc. increased its position in shares of Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $210.65 on Wednesday. The business’s 50-day moving average price is $225.79 and its 200-day moving average price is $246.04. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The firm has a market capitalization of $150.56 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.66 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business earned $2.09 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. Danaher’s payout ratio is currently 24.24%.

Analysts Set New Price Targets

DHR has been the topic of a number of recent analyst reports. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research report on Friday, December 13th. Jefferies Financial Group decreased their price target on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Raymond James restated a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. JPMorgan Chase & Co. decreased their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Citigroup decreased their price target on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.10% of the stock is owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.